Christopher A. Kroeger, Chief Executive Officer of MapLight Therapeutics, Inc. (NASDAQ:MPLT), reported the sale of company common stock totaling approximately $5.44 million over several transactions between July 15 and July 17, 2026.
Mr. Kroeger disposed of a total of 147,639 shares of MapLight Therapeutics Voting Common Stock. The shares were sold at prices ranging from $36.00 to $37.96 per share. These transactions represent shares required to be sold to cover statutory tax withholding obligations in connection with the vesting of restricted stock units. The sales were mandated by the issuer’s equity incentive plans to fund minimum statutory tax withholding obligations through a “sell to cover” transaction and do not represent discretionary sales by Mr. Kroeger.
Following these transactions, Mr. Kroeger directly holds 1,246,455 shares of MapLight Therapeutics Voting Common Stock. Additionally, 101,190 shares are held indirectly through the C&M Kroeger Nominee Trust, of which Mr. Kroeger is co-trustee with his spouse and has voting and dispositive power.
In other recent news, MapLight Therapeutics has been the focus of several analyst reports and corporate developments. Needham raised its price target for MapLight Therapeutics to $45 from $42, maintaining a Buy rating, following promising trial data for its lead candidate aimed at treating schizophrenia. Raymond James also initiated coverage with a strong buy rating and set a price target of $46, citing favorable risk/reward dynamics for the company’s ongoing Phase 2 trial. H.C. Wainwright reiterated a Buy rating and a $45 price target after MapLight reported top-line results from a Phase 2 study on autism spectrum disorder, which involved 161 participants. The firm also highlighted potential in the muscarinic receptor activation mechanism during a recent conference. Additionally, MapLight Therapeutics announced the appointment of Martin Babler and Troy Cox to its Board of Directors, following the departure of two previous board members. Babler will join the Audit Committee, while Cox will chair the Nominating and Corporate Governance Committee. These recent developments underline the company’s ongoing efforts in advancing its clinical programs and strengthening its leadership team.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
